MX394540B - Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion. - Google Patents

Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.

Info

Publication number
MX394540B
MX394540B MX2019012507A MX2019012507A MX394540B MX 394540 B MX394540 B MX 394540B MX 2019012507 A MX2019012507 A MX 2019012507A MX 2019012507 A MX2019012507 A MX 2019012507A MX 394540 B MX394540 B MX 394540B
Authority
MX
Mexico
Prior art keywords
oxooxazolidin
oxazepin
dihydrobenzo
propanamide
imidazo
Prior art date
Application number
MX2019012507A
Other languages
English (en)
Spanish (es)
Other versions
MX2019012507A (es
Inventor
Chong Han
Karthik Nagapudi
Paroma Chakravarty
Scott Savage
Sean M Kelly
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62492573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX394540(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019012507A publication Critical patent/MX2019012507A/es
Publication of MX394540B publication Critical patent/MX394540B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
MX2019012507A 2017-04-28 2018-04-26 Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion. MX394540B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491812P 2017-04-28 2017-04-28
PCT/EP2018/060820 WO2018197653A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Publications (2)

Publication Number Publication Date
MX2019012507A MX2019012507A (es) 2019-12-19
MX394540B true MX394540B (es) 2025-03-21

Family

ID=62492573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012507A MX394540B (es) 2017-04-28 2018-04-26 Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.

Country Status (13)

Country Link
US (4) US20180339997A1 (https=)
EP (2) EP4534148A3 (https=)
JP (2) JP6998969B2 (https=)
KR (1) KR102342776B1 (https=)
CN (1) CN110650963B (https=)
AU (1) AU2018259089B2 (https=)
CA (1) CA3048591A1 (https=)
ES (1) ES3027566T3 (https=)
IL (3) IL298518B2 (https=)
MX (1) MX394540B (https=)
PL (1) PL3615541T3 (https=)
TW (1) TWI826373B (https=)
WO (1) WO2018197653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
WO2018109204A1 (en) 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
ES3027566T3 (en) * 2017-04-28 2025-06-16 Hoffmann La Roche Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
CN112313202A (zh) * 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
KR20220034129A (ko) * 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
TWI886177B (zh) * 2019-11-25 2025-06-11 大陸商上海翰森生物醫藥科技有限公司 含三并環類衍生物的鹽或晶型及其醫藥組成物
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
TWI801730B (zh) * 2020-04-07 2023-05-11 神雲科技股份有限公司 具系統設定資料同步功能的伺服器
JP7625091B2 (ja) * 2021-01-29 2025-01-31 メッドシャイン ディスカバリー インコーポレイテッド 三環式化合物及びその使用
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
MY160064A (en) * 2009-09-28 2017-02-15 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
KR20180093138A (ko) 2013-12-16 2018-08-20 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
WO2018109204A1 (en) * 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
ES3027566T3 (en) 2017-04-28 2025-06-16 Hoffmann La Roche Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Also Published As

Publication number Publication date
JP2021181446A (ja) 2021-11-25
TW201843160A (zh) 2018-12-16
IL298518B2 (en) 2025-05-01
AU2018259089B2 (en) 2022-05-12
EP3615541A1 (en) 2020-03-04
US11591345B2 (en) 2023-02-28
US20200399286A1 (en) 2020-12-24
KR102342776B1 (ko) 2021-12-23
EP3615541C0 (en) 2025-03-19
WO2018197653A1 (en) 2018-11-01
EP3615541B1 (en) 2025-03-19
CN110650963A (zh) 2020-01-03
IL267464B1 (en) 2023-01-01
IL267464A (en) 2019-08-29
TWI826373B (zh) 2023-12-21
AU2018259089A9 (en) 2019-10-10
KR20190133724A (ko) 2019-12-03
ES3027566T3 (en) 2025-06-16
PL3615541T3 (pl) 2025-06-23
WO2018197653A9 (en) 2019-09-19
MX2019012507A (es) 2019-12-19
JP2020517713A (ja) 2020-06-18
IL317762A (en) 2025-02-01
IL267464B2 (en) 2023-05-01
IL298518A (en) 2023-01-01
US20180339997A1 (en) 2018-11-29
US20230167128A1 (en) 2023-06-01
BR112019013292A2 (pt) 2019-12-10
CA3048591A1 (en) 2018-11-01
JP6998969B2 (ja) 2022-02-10
US12410189B2 (en) 2025-09-09
CN110650963B (zh) 2022-09-27
AU2018259089A1 (en) 2019-07-04
IL298518B1 (en) 2025-01-01
US20210094970A1 (en) 2021-04-01
US11028100B2 (en) 2021-06-08
EP4534148A3 (en) 2025-05-21
EP4534148A2 (en) 2025-04-09

Similar Documents

Publication Publication Date Title
MX394540B (es) Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
TN2019000133A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
MX377921B (es) Proceso para la preparacion de (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida
WO2012044727A3 (en) Manufacturing process for pyrimidine derivatives
WO2016063294A3 (en) Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
WO2018029711A3 (en) Process for the preparation of venetoclax
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
MY209751A (en) Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
HK1255014A1 (zh) 制备取代5，6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
MX356804B (es) Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos.
WO2016010662A9 (en) Quinoxaline compounds, method for preparing the same and use thereof
WO2012038971A3 (en) Novel polymorphs of febuxostat
WO2015104602A3 (en) A process for the preparation of anagliptin and its intermediates thereof
WO2016027211A3 (en) Process for the preparation of cinacalcet and its pharmaceutically acceptable salts
TH101974B (th) วิธีการสำหรับการเตรียมเบนซีน ซึ่งถูกแทนที่ด้วยไตรคลอโรเมธิล
MX2016014692A (es) Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.
TN2013000094A1 (en) Manufacturing process for pyrimidine derivatives
MY197130A (en) Tlr7 agonist crystalline form a, preparation method and use thereof